Results 121 to 130 of about 10,477 (203)

Impact of methotrexate and etanercept drugs on serum levels of soluble toll-like receptor-2 in Iraqi patients with rheumatoid arthritis

Egyptian Rheumatology and Rehabilitation
Background Methotrexate and Etanercept are common treatment strategies for rheumatoid arthritis (RA) and are classified as conventional synthetic and biologic disease-modifying antirheumatic drugs respectively.
Muna R. Hameed, Faiq I. Gorial, Fayhaa M. khaleel   +2 more
doaj   +1 more source

Evaluation of Discontinuation and Re‐Initiation of Biologic Therapies in Psoriasis: Real‐World Data

International Journal of Dermatology, EarlyView.
The cumulative probability of remaining relapse‐free following biologic therapy discontinuation was 35.6%, 19%, 11.6%, and 9.1% at 6, 12, 18, and 24 months, respectively. Prolonged relapse durations were associated with a low baseline PASI score, the presence of a PASI 90 response at discontinuation, the absence of triggering factors, and the use of IL‐
Ahmet Taha Aydemir, Nihal Kundakcı
wiley   +1 more source

Treatment of erythrodermic psoriasis with etanercept

, 2006
Background Severe variants of psoriasis, such as erythrodermic psoriasis, may be associated with serious morbidity and mortality. Current treatment options for erythrodermic psoriasis are limited, unsatisfactory and potentially associated with organ ...
Papoutsaki M, de Felice C, Esposito M, Mazzotta A, Chimenti S   +4 more
core   +1 more source

Mechanism and Efficacy of Etanercept in Treating Autoimmune-like Manifestations of Coronavirus Disease 2019 in elderly individuals

Immunobiology
During the COVID-19 pandemic, extensive research focused on universal treatments, but few studies addressed treatment regimens for elderly patients. This study aimed to evaluate the effects of etanercept, a TNF inhibitor, in elderly individuals with ...
Lizhong Zhang, Hongyi Li, Lei Shi, Jie Geng, Haojun Zhang, Haoran Chen, Peng Zhao, Yang Xiao, Jinqi Lu, Zhilun Li, Hongbin Pu, Chuandong Hou, Chenghui Li, Chumeng Gao, Xia Song, Zhuocheng Bao, Bing Zhai, Bo Guo, Bo Yang, Xuechun Lu, Qi Yu   +20 more
doaj   +1 more source

Emerging Roles of PSTPIP2 in Autoimmunity: From Mechanism to Therapeutic Implications

Immunology, EarlyView.
PSTPIP2 acts as a key brake on myeloid inflammation by suppressing IL‐1β‐driven signalling, macrophage dysregulation and inflammation‐associated bone remodelling. Its emerging roles in CRMO/CMO, rheumatoid arthritis, SAPHO syndrome and bullous pemphigoid support its potential as a biomarker and therapeutic target.
Erdong Zhang, Fengyu Liu, Yongle Wei, Guoqiang Li, Liujie Zheng, Lin Jin, Feng Luan, Yingze Zhang, Ling Wang, Zhiyong Hou   +9 more
wiley   +1 more source

Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment

, 2017
Aim: Etanercept has shown to mediate a favorable effect on immune-mediated inflammatory diseases (IMID), including plaque psoriasis. Therapeutic drug monitoring (TDM) of etanercept could improve clinical outcome and cost-effectiveness.
Koch, Birgit C. P., Prens, Errol P., van Bezooijen, Ji S., te Velthuis, Henk, van Doorn, Martijn B. A., Schreurs, Marco W. J., van Gelder, Teun   +6 more
core   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data

BMC Rheumatology
Background Safety remains a significant concern for biologic drugs, and studies are needed to ensure a comparable safety profile for biosimilars and their legacy treatments.
Marina G. Birck, Luck Lukusa, Denis Choquette, Gilles Boire, Walter P. Maksymowych, Harminder Singh, Waqqas Afif, Sasha Bernatsky   +7 more
doaj   +1 more source

Treatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Systematic review of 108 studies with a total of 182 patients with interstitial granulomatous dermatitis (IGD). IGD was frequently associated with systemic conditions or drug exposure. Management includes careful medication review and prompt withdrawal of potential triggers. Corticosteroids (systemic and topical) were commonly effective, while biologic
Francesco Bellinato, Sara Salvagno, Chiara Colato, Paolo Gisondi, Giampiero Girolomoni   +4 more
wiley   +1 more source

Etanercept Enhances Preservation of Osteochondral Allograft Viability

, 2011
Background: Osteochondral allografts are an increasingly popular treatment for the repair of articular cartilage lesions. Current tissue bank protocols require bacteriological testing that takes from 21 to 28 days to process.
William D. Bugbee, Robert M. Healey, David Amiel, Michael S. Linn, Frederick L. Harwood, Derek C. Chase   +5 more
core   +1 more source